FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386001142> ?p ?o ?g. }

• W4386001142 endingPage "4638" @default.
• W4386001142 startingPage "4626" @default.
• W4386001142 abstract "Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy, showed deep, durable responses in patients with RRMM in the pivotal phase 2 KarMMa trial (NCT03361748). Healthcare resource utilization (HCRU) and costs were estimated for ide-cel-treated patients in the KarMMa trial. Post-infusion costs were estimated based on HCRU data, including facility care, diagnostics, medications, and procedures. Length of stay (LOS) was extracted for inpatient and intensive care unit (ICU) care. All patients had a 14-day post-infusion inpatient stay per trial protocol. Analyses were conducted for patients treated in the United States (US), who received the ide-cel target dose of 450 × 106 CAR + T cells and assuming a 7-day inpatient stay. Overall, 128 patients received ide-cel and were included in this analysis. Mean age was 60 years, 59% were men, and 81% were white. Mean total LOS was 23.9 days. Total estimated costs over 24 months post-infusion were US$115,614 per patient, driven by facility costs (75%; $86,385). Most costs were incurred in the first month (58%; $67,259). The scenario analysis assuming a 7-day inpatient stay showed estimated 24-month costs of $92,294. For the 54 (42%) patients who received ide-cel high dose, total costs over 24 months were $113,298 per patient. Extrapolation of costs based on HCRU data from patients receiving single-infusion of ide-cel in the KarMMa trial showed substantially reduced HCRU and costs over 2 years after initial treatment. Most costs were incurred during the first month after ide-cel infusion, likely attributable to the 14-day inpatient stay required by the trial protocol. These findings suggest a nominal, incremental monthly cost of care immediately after treatment, which may be lower in routine clinical practice." @default.
• W4386001142 created "2023-08-20" @default.
• W4386001142 creator A5006260782 @default.
• W4386001142 creator A5008762690 @default.
• W4386001142 creator A5010567598 @default.
• W4386001142 creator A5037561630 @default.
• W4386001142 creator A5042341419 @default.
• W4386001142 creator A5054347018 @default.
• W4386001142 creator A5077889808 @default.
• W4386001142 date "2023-08-19" @default.
• W4386001142 modified "2023-10-12" @default.
• W4386001142 title "Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial" @default.
• W4386001142 cites W1989471045 @default.
• W4386001142 cites W2079617490 @default.
• W4386001142 cites W2162771614 @default.
• W4386001142 cites W2165974443 @default.
• W4386001142 cites W2486629951 @default.
• W4386001142 cites W2625253716 @default.
• W4386001142 cites W2770457793 @default.
• W4386001142 cites W2892065592 @default.
• W4386001142 cites W2921533600 @default.
• W4386001142 cites W2979807505 @default.
• W4386001142 cites W3015964670 @default.
• W4386001142 cites W3022544575 @default.
• W4386001142 cites W3110289189 @default.
• W4386001142 cites W3118284675 @default.
• W4386001142 cites W3128646645 @default.
• W4386001142 cites W3133229959 @default.
• W4386001142 cites W3171259150 @default.
• W4386001142 cites W3208162414 @default.
• W4386001142 cites W4200018236 @default.
• W4386001142 cites W4210734847 @default.
• W4386001142 cites W4297338220 @default.
• W4386001142 cites W4309929751 @default.
• W4386001142 cites W4367834115 @default.
• W4386001142 doi "https://doi.org/10.1007/s12325-023-02623-w" @default.
• W4386001142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37597153" @default.
• W4386001142 hasPublicationYear "2023" @default.
• W4386001142 type Work @default.
• W4386001142 citedByCount "0" @default.
• W4386001142 crossrefType "journal-article" @default.
• W4386001142 hasAuthorship W4386001142A5006260782 @default.
• W4386001142 hasAuthorship W4386001142A5008762690 @default.
• W4386001142 hasAuthorship W4386001142A5010567598 @default.
• W4386001142 hasAuthorship W4386001142A5037561630 @default.
• W4386001142 hasAuthorship W4386001142A5042341419 @default.
• W4386001142 hasAuthorship W4386001142A5054347018 @default.
• W4386001142 hasAuthorship W4386001142A5077889808 @default.
• W4386001142 hasBestOaLocation W43860011421 @default.
• W4386001142 hasConcept C121332964 @default.
• W4386001142 hasConcept C126322002 @default.
• W4386001142 hasConcept C142424586 @default.
• W4386001142 hasConcept C194828623 @default.
• W4386001142 hasConcept C2776364478 @default.
• W4386001142 hasConcept C535046627 @default.
• W4386001142 hasConcept C71924100 @default.
• W4386001142 hasConcept C87355193 @default.
• W4386001142 hasConceptScore W4386001142C121332964 @default.
• W4386001142 hasConceptScore W4386001142C126322002 @default.
• W4386001142 hasConceptScore W4386001142C142424586 @default.
• W4386001142 hasConceptScore W4386001142C194828623 @default.
• W4386001142 hasConceptScore W4386001142C2776364478 @default.
• W4386001142 hasConceptScore W4386001142C535046627 @default.
• W4386001142 hasConceptScore W4386001142C71924100 @default.
• W4386001142 hasConceptScore W4386001142C87355193 @default.
• W4386001142 hasFunder F4320307115 @default.
• W4386001142 hasIssue "10" @default.
• W4386001142 hasLocation W43860011421 @default.
• W4386001142 hasLocation W43860011422 @default.
• W4386001142 hasLocation W43860011423 @default.
• W4386001142 hasOpenAccess W4386001142 @default.
• W4386001142 hasPrimaryLocation W43860011421 @default.
• W4386001142 hasRelatedWork W1966504330 @default.
• W4386001142 hasRelatedWork W1974041167 @default.
• W4386001142 hasRelatedWork W1979139803 @default.
• W4386001142 hasRelatedWork W2030889776 @default.
• W4386001142 hasRelatedWork W2037631372 @default.
• W4386001142 hasRelatedWork W2040058909 @default.
• W4386001142 hasRelatedWork W2070567609 @default.
• W4386001142 hasRelatedWork W2073527559 @default.
• W4386001142 hasRelatedWork W2159000141 @default.
• W4386001142 hasRelatedWork W2391409986 @default.
• W4386001142 hasVolume "40" @default.
• W4386001142 isParatext "false" @default.
• W4386001142 isRetracted "false" @default.
• W4386001142 workType "article" @default.